Inbeeo’s client, a specialty pharmaceutical company, was preparing for the Wave 1 launch of an ‘incremental innovation’ product. They required health economic tools to support HTA submissions and regional negotiations, with a recognition that the indication was not a priority for many payers, who would need to see clear value for them.
With the product an ‘incremental innovation’ facing significant pressure from generics, the value story was predicated on a clear demonstration of financial savings. As abbreviated submissions and regional negotiations formed the backbone of the market access pathway across target markets, developing a compelling but easily-understandable budget impact tool was critical for success.
Following discussions with all relevant affiliates to establish their specific needs, Inbeeo developed a global budget impact model, which was fully adaptable to suit both national and regional payers’ requirements. Inbeeo then worked with affiliates to optimize the model for their in-country submissions.
Inbeeo developed and adapted a budget impact model to support successful launches of a specialty product across all Wave 1 markets, in the face of significant genericization.